<DOC>
	<DOCNO>NCT00695448</DOCNO>
	<brief_summary>This open-label , multi-center Phase I study conduct define recommend Phase 2 dose , toxicity profile , pharmacokinetics biologically active dose range GSK1059615 .</brief_summary>
	<brief_title>Phase I Open-Label , Dose-Escalation Study GSK1059615 Patients With Solid Tumors Lymphoma</brief_title>
	<detailed_description />
	<criteria>Written inform consent provide . 18 year old old . Histologically cytologically confirm diagnosis solid tumor malignancy lymphoma responsive accepted standard therapy standard curative therapy . Performance Status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . A life expectancy &gt; 12 week . Able swallow retain oral medication . A male eligible enter participate study either : agrees abstain sexual intercourse first dose study drug 21 day last dose study medication , agree use condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository first dose study drug 21 day last dose study medication , surgically sterile . NOTE : Male patient must use contraception prevent pregnancy female partner prevent exposure partner semen mean ( refer protocol ) . A female eligible enroll study : Nonchild bear potential ( i.e. , physiologically incapable become pregnant ) include woman characterize least one following : Has hysterectomy Has bilateral oophorectomy ( ovariectomy ) Has bilateral tubal ligation Is postmenopausal ( total cessation menses ≥ 1 year ) Childbearing potential , negative serum pregnancy test screening , agree one follow least 2 week prior first dose study drug 21 day last dose study medication : Use intrauterine device ( IUD ) document failure rate le 1 % per year . Have intercourse vasectomize partner sterile sole sexual partner woman . Complete abstinence sexual intercourse . Use double barrier contraception define condom spermicidal jelly , foam , suppository , film ; OR diaphragm spermicide ; OR male condom diaphragm . NOTE : Oral contraceptive reliable due potential drugdrug interaction . Adequate organ system function define protocol . Use investigational anticancer drug within 28 day 5 halflives precede first dose GSK1059615 . Chemotherapy within last 3 week ( 6 week prior nitrosourea mitomycin C ) . Chemotherapy regimens give continuously weekly basis limit potential delayed toxicity permit approval GSK medical monitor administer least 2 week prior first dose study drug . Trastuzumab within last 4 week . Any major surgery , radiotherapy , immunotherapy within last 4 week . Prior use PI3K inhibitor . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug . ( To date know FDA approve drug chemically relate GSK1059615 ) . Current use prohibit medication require medication treatment GSK1059615 per protocol . Current use warfarin therapeutic anticoagulation . NOTE : Low molecular weight heparin prophylactic lowdose warfarin permit . PT/PTT must meet inclusion criterion . Patients take warfarin must INR follow closely . Presence active gastrointestinal disease condition know interfere significantly absorption , distribution , metabolism , excretion drug . Unresolved toxicity great Grade 1 previous anticancer therapy except alopecia . Patients stable Grade 2 neuropathy enrol approval GSK Medical Monitor . QTc interval ≥ 480 msec . History acute coronary syndrome ( include unstable angina myocardial infarction ) , atrial fibrillation , coronary angioplasty , stenting within past 24 week . Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system . Symptomatic untreated leptomeningeal brain metastasis . Patients previously treat condition asymptomatic corticosteroid P450inducing antiepileptic medication least 2 month permit . Primary malignancy central nervous system . Psychological , familial , sociological , geographical condition permit compliance protocol . Concurrent condition investigator 's opinion would jeopardize compliance protocol . Nursing female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Phosphoinositide 3-kinase inhibitor</keyword>
	<keyword>solid tumor</keyword>
</DOC>